EBS earnings analysis
What we found in EBS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Emergent BioSolutions reported Q1 2026 earnings with total revenue of $156.1 million, decreasing by 30% compared to Q1 2025. The company achieved an EPS of $0.21, surpassing the estimated loss of $0.25, while experiencing significant declines in its MCM product sales. Management remains cautiously optimistic, projecting Q2 2026 revenues between $170 million and $185 million, driven by improved operations and product sales.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS Surprising Improvement
- Reported EPS of $0.21 compared to an expected loss of $0.25, translating to a surprise of 1.84%.
- Improved Cash Position
- Cash and cash equivalents decreased to $160.3 million from $205.4 million, but available borrowing capacity remains strong.
- Operational Expense Reduction
- Total operating expenses decreased by 15% to $145.6 million from $172.3 million, highlighting cost management efforts.
- Decline in Interest Expense
- Interest expense decreased by 25% to $11.0 million from $14.7 million due to lower outstanding debt.
- Segment Performance Review
- MCM Product revenue dropped 35% from $156.6 million in Q1 2025 to $101.8 million in Q1 2026.
- Share Repurchase Program Ongoing
- $9.1 million used in stock repurchases in Q1 2026, with $46.5 million remaining under the repurchase plan.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Significant Revenue Decline
- Total revenues decreased by $66.1 million, or 30%, due to lower MCM product sales.
- High Cost of Debt
- Total debt remained stable at $573.6 million, maintaining high financing costs amid decreased revenues.
- Reliance on Third-Party Manufacturers
- Dependence on third-party manufacturers for product supply can disrupt operations and affect profitability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.21
- Gross margin
- 41%
- Operating margin
- 6.7%
- Segment
- Commercial Products
- Segment
- MCM Products
What they said about what is next.
Q2 2026 guidance reflects expectations of improved operations and product sales.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing EBS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever